• Overview of the 2018 US Food and Drug Administration Circulatory System Devices Panel Meeting on Device-Based Therapies for hypertension

    • Posted: 11/18/2019
    • Author:

       

      Nauman Khalid, Toby Rogers, Evan Shlofmitz, Yuefeng Chen, ... Ron Waksman

       

    • CRM2019

    Highlights

    • Hypertension is the leading preventable cause of MI, stroke, and death worldwide.

    • FDA's Circulatory System Devices Panel discussed device-based management of HTN

    • Device targets include RDN, baroreflex amplification and hemodynamic modification.

    • Summary of published data and ongoing randomized clinical trials is presented.

    • Panel and industry supported renaissance of device-based antihypertensive therapies

    Author bio

    Cardiovascular Revascularization Medicine, 2019-10-01, Volume 20, Issue 10, Pages 891-896, Copyright © 2019 Elsevier Inc.

     

    Source:

    Read the full article on Science Direct: Overview of the 2018 US Food and Drug Administration Circulatory System Devices Panel Meeting on Device-Based Therapies for hypertension

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details